Patricia M McGowan

Summary

Affiliation: University College Dublin
Country: Ireland

Publications

  1. doi ADAM-17: a novel therapeutic target for triple negative breast cancer
    P M McGowan
    Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, Dublin, Ireland
    Ann Oncol 24:362-9. 2013
  2. pmc Notch1 inhibition alters the CD44hi/CD24lo population and reduces the formation of brain metastases from breast cancer
    Patricia M McGowan
    Department of Medical Biophysics, University of Western Ontario, London, Ontario, Canada
    Mol Cancer Res 9:834-44. 2011
  3. pmc Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines
    Aisling Pierce
    Education and Research Centre, St Vincent s University Hospital, Dublin, Ireland
    Cancer Biol Ther 14:537-45. 2013
  4. doi Role of ADAMs in cancer formation and progression
    Michael J Duffy
    Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, UCD School of Medicine and Medical Science, University College Dublin, Dublin, Ireland
    Clin Cancer Res 15:1140-4. 2009
  5. doi Targeted therapy for triple-negative breast cancer: where are we?
    Michael J Duffy
    UCD Clinical Research Centre, St Vincent s University Hospital, Dublin, Ireland
    Int J Cancer 131:2471-7. 2012
  6. ncbi ADAM-17 expression in breast cancer correlates with variables of tumor progression
    Patricia M McGowan
    Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, Ireland
    Clin Cancer Res 13:2335-43. 2007
  7. doi Micrometastatic disease and metastatic outgrowth: clinical issues and experimental approaches
    Patricia M McGowan
    Department Medical Biophysics, University of Western Ontario, London, ON, Canada
    Future Oncol 5:1083-98. 2009
  8. pmc The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer?
    Michael J Duffy
    Department of Pathology and Laboratory Medicine, St, Vincent s University Hospital, Dublin 4, Ireland
    Clin Proteomics 8:9. 2011
  9. ncbi The role of ADAMs in disease pathophysiology
    Michael J Duffy
    Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, Dublin 4, Ireland
    Clin Chim Acta 403:31-6. 2009

Detail Information

Publications9

  1. doi ADAM-17: a novel therapeutic target for triple negative breast cancer
    P M McGowan
    Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, Dublin, Ireland
    Ann Oncol 24:362-9. 2013
    ..e., those with triple-negative (TN) disease]. ADAM-17 is a protease involved in the activations of several ligands that bind to and promotes intracellular signalling from the EGFR/HER family of receptors...
  2. pmc Notch1 inhibition alters the CD44hi/CD24lo population and reduces the formation of brain metastases from breast cancer
    Patricia M McGowan
    Department of Medical Biophysics, University of Western Ontario, London, Ontario, Canada
    Mol Cancer Res 9:834-44. 2011
    ..001; Kruskal-Wallis). These data suggest that the CSC phenotype contributes to the development of brain metastases from breast cancer, and this may arise in part from increased Notch activity...
  3. pmc Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines
    Aisling Pierce
    Education and Research Centre, St Vincent s University Hospital, Dublin, Ireland
    Cancer Biol Ther 14:537-45. 2013
    ..e., whether HER2-positive, estrogen receptor (ER)-positive or triple-negative. Olaparib, in combination with a selective CDK1 inhibitor or a pan HER inhibitor, is a potential new approach for treating breast cancer...
  4. doi Role of ADAMs in cancer formation and progression
    Michael J Duffy
    Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, UCD School of Medicine and Medical Science, University College Dublin, Dublin, Ireland
    Clin Cancer Res 15:1140-4. 2009
    ..The ADAMs are thus a new family of potential targets for the treatment of cancer, especially malignancies that are dependent on human epidermal growth factor receptor ligands or tumor necrosis factor-alpha...
  5. doi Targeted therapy for triple-negative breast cancer: where are we?
    Michael J Duffy
    UCD Clinical Research Centre, St Vincent s University Hospital, Dublin, Ireland
    Int J Cancer 131:2471-7. 2012
    ..The rational way forward for treating these patients is likely to be biomarker-driven, combination targeted therapies or combination of targeted therapy with cytotoxic chemotherapy...
  6. ncbi ADAM-17 expression in breast cancer correlates with variables of tumor progression
    Patricia M McGowan
    Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, Ireland
    Clin Cancer Res 13:2335-43. 2007
    ..524, P < 0.0001, n = 73 and active form: r = 0.365, P = 0.002, n = 73). Our results support the hypothesis that ADAM-17 is involved in breast cancer progression...
  7. doi Micrometastatic disease and metastatic outgrowth: clinical issues and experimental approaches
    Patricia M McGowan
    Department Medical Biophysics, University of Western Ontario, London, ON, Canada
    Future Oncol 5:1083-98. 2009
    ..Elucidation of the molecular pathways involved in dormancy will advance clinical understanding and may suggest new avenues for treatment to inhibit the revival of these dormant cells, thereby reducing cancer mortality rates...
  8. pmc The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer?
    Michael J Duffy
    Department of Pathology and Laboratory Medicine, St, Vincent s University Hospital, Dublin 4, Ireland
    Clin Proteomics 8:9. 2011
    ..Furthermore, a number of selective ADAM inhibitors, especially against ADAM10 and ADAM17, have been shown to have anti-cancer effects. At least one of these inhibitors is now undergoing clinical trials in patients with breast cancer...
  9. ncbi The role of ADAMs in disease pathophysiology
    Michael J Duffy
    Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, Dublin 4, Ireland
    Clin Chim Acta 403:31-6. 2009
    ..Further work is required in order to establish a causative role for ADAMs in rheumatoid arthritis, Alzheimer's disease, cardiac hypertrophy and asthma...